Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Investigations – page 7

  • 79 clinical trials
  • 29 recruiting
  • 93 conditions
  • 21 countries

Conditions in this area

93 conditions with trials, the busiest first

Drug level12Human epidermal growth factor receptor negative8Fallopian tube cancer6Peritoneal cancer index6Breast cancer5Hormone receptor positive breast cancer5Allergy test4Allergy test positive3BRAF V600E mutation positive3Breast cancer female3Breast cancer metastatic3Hormone receptor positive HER2 negative breast cancer3Magnetic resonance imaging3Ovarian cancer recurrent3Colonoscopy2Cortisol abnormal2Hepatitis B e antigen negative2Hepatitis B virus test2Hypersensitivity2Infertility2Infertility female2Infertility tests normal2Non-small cell lung cancer stage IV2Ovarian cancer2+69

Clinical trials in Investigations

79 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

79 clinical trials

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Acute myocardial infarction+5

Not recruiting

Study on the Effects of Zalunfiban for Patients with ST-Elevation Myocardial Infarction (Heart Attack)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zalunfiban
  • Sponsor:Celecor Therapeutics Inc.

Fallopian tube cancer+1

Not recruiting

Study of Pembrolizumab, MK-4830, and Chemotherapy for Patients with High-Grade Serous Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Infertility+2

Not recruiting

Study on Progesterone for Improving Birth Rates in Couples with Unexplained Infertility Undergoing Mild Ovarian Stimulation and Intrauterine Insemination

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Progesterone, Micronised
  • Sponsor:Universitair Medisch Centrum Utrecht

Magnetic resonance imaging+1

Not recruiting

Study Comparing Gadoquatrane with Gadoteric Acid, Gadoteridol, and Gadobutrol for MRI in Patients with Non-CNS Conditions

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Bayer AG

Breast cancer metastatic+2

Not recruiting

Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daehwa Pharmaceutical Co. Ltd.

Substances studied in this area

The therapies tested most often in Investigations trials.

Sodium Chloride11 clinical trialsPaclitaxel6 clinical trialsHistamine Dihydrochloride5 clinical trialsPembrolizumab4 clinical trialsAbemaciclib3 clinical trialsCapecitabine3 clinical trialsCarboplatin3 clinical trialsDoxorubicin Hydrochloride3 clinical trialsGadobutrol3 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.